Statin Impact on Hepatic Decompensation

Tanta University100 enrolled

Overview

The study aims to evaluate the impact of statin on hepatic decompensation.

Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

100

Conditions

Quality of Life the Incidence of Whole Complications Resultant From Decompensated Liver

Interventions

Atorvastatin 20mgDRUG

active arm

PlaceboDRUG

placebo arm

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Admissibility measures were age ranged from 18 to 75, with a medical diagnosis of decompensated liver cirrhosis built on standard clinical symptoms, laboratory tests, imaging appearances and/or liver biopsy. Decompensation of the disease was labeled by to the lowest degree having one episode of severe complications, including ascites, SBP, jaundice, EGVB and HE.8 All participants were ready to be enrolled and had signed up the informed consent. The foremost exclusion criteria involved the following: (1) life-deadly leukocytopenia (WBCs \< 1 × 109/l); (2) Pregnant women or lactating mother; (3) patients diagnosed to have primary or secondary liver cancer.

Locations (1)

Tanta University

Tanta, Egypt

Outcomes

Primary Outcomes

impact on decompensation

change in recurrence of cirrhosis related complications

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.